{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:55:48Z","timestamp":1790924148984,"version":"4.1.0"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Bladder cancer research has experienced a rapid increase in publication output with the emergence of new themes in diagnosis and treatment. The expanding literature makes it challenging to identify overarching trends and key developments. Therefore, a bibliometric analysis is warranted to systematically evaluate global research patterns, thematic evolution, and influential contributions within this dynamic field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A bibliometric analysis was conducted using the Scopus database to retrieve articles and reviews on bladder cancer published between 2016 and December 2025. The search was performed in titles, abstracts, and keywords using predefined bladder cancer-related terms. Data were analyzed using VOSviewer and the Bibliometrix package in R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Between 2016 and 2025, a total of 49,014 publications related to bladder cancer, limited to Articles and Reviews indexed in Scopus, were included in the bibliometric analyses. The most frequent terms in bladder cancer research over the past 10\u2009years were urothelial carcinoma, cancer immunotherapy, prognosis, biomarkers, chemotherapy, and radical cystectomy. The most cited terms included survival, cancer immunotherapy, and tumor microenvironment, and trending topics were tumor microenvironment, immune checkpoint inhibitors, and muscle-invasive bladder cancer. Thematic mapping identified one motor theme (urothelial carcinoma, chemotherapy, radical cystectomy) and two niche themes, including \u201ccell cycle,\u201d \u201cmetastasis,\u201d and \u201capoptosis,\u201d and \u201cmortality,\u201d \u201cupper urinary tract urothelial carcinoma,\u201d and \u201cmeta-analysis.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Frequent keywords such as biomarkers, prognosis, non-muscle invasive bladder cancer, chemotherapy, and radical cystectomy, together with highly cited and recently prominent terms including tumor microenvironment and immune checkpoint inhibitors, reflect areas of substantial research activity and evolving scientific interest. Thematic evolution analyses further indicate changing patterns in keyword co-occurrence over time, particularly for non-muscle invasive bladder cancer, upper urinary tract urothelial carcinoma, and meta-analysis. The translation of these trends into clinical practice requires further evidence synthesis, clinical trials, guideline evaluation, and broader stakeholder input.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261483766","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:20:16Z","timestamp":1790594416000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global trends and hotspots in bladder cancer: A bibliometric analysis (2016\u20132025)"],"prefix":"10.1177","author":[{"given":"Rakesh","family":"Heer","sequence":"first","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"},{"name":"Department of Urology, Imperial College Healthcare National Health Service (NHS) Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-2323","authenticated-orcid":false,"given":"Mehrdad","family":"Farrokhi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","unstructured":"Barani M Hosseinikhah SM Rahdar A et al. Nanotechnology in bladder cancer: diagnosis and treatment. Cancers 2021; 13: 2214. https:\/\/doi.org\/10.3390\/cancers13092214","DOI":"10.3390\/cancers13092214"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","unstructured":"Claps F Pavan N Ongaro L et al. BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets. Int J Mol Sci 2023; 24: 20230809. https:\/\/doi.org\/10.3390\/ijms241612596","DOI":"10.3390\/ijms241612596"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","unstructured":"Han J Gu X Li Y et al. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother 2020; 129: 110393. https:\/\/doi.org\/10.1016\/j.biopha.2020.110393","DOI":"10.1016\/j.biopha.2020.110393"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","unstructured":"Lopez-Beltran A Cookson MS Guercio BJ et al. Advances in diagnosis and treatment of bladder cancer. BMJ 2024; 384: e076743. https:\/\/doi.org\/10.1136\/bmj-2023-076743","DOI":"10.1136\/bmj-2023-076743"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","unstructured":"Nassif EF Thibault C Oudard S et al. Precision immunity: immunoscore and neoadjuvant treatment in bladder cancer. OncoImmunology 2021; 10: 1888488. https:\/\/doi.org\/10.1080\/2162402X.2021.1888488","DOI":"10.1080\/2162402X.2021.1888488"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","unstructured":"Patel VG Oh WK Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 2020; 70: 404\u2013423. https:\/\/doi.org\/10.3322\/caac.21631","DOI":"10.3322\/caac.21631"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","unstructured":"Tang Y Wang L Liu H et al. Advances in intravesical therapy for non-muscle-invasive bladder cancer. Crit Rev Oncol Hematol 2026; 222: 105271. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105271","DOI":"10.1016\/j.critrevonc.2026.105271"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","unstructured":"Cigliola A Maiorano BA Dengur D et al. The management of muscle invasive bladder cancer: state of the art and future perspectives. Cancers 2025; 17: 20251217. https:\/\/doi.org\/10.3390\/cancers17244017","DOI":"10.3390\/cancers17244017"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","unstructured":"Hassan IN Ibrahim MNH Abuassa N. FDA approves durvalumab for muscle-invasive bladder cancer: a new standard in neoadjuvant and adjuvant therapy. Ann Med Surg 2025; 87: 4011\u20134013. https:\/\/doi.org\/10.1097\/MS9.0000000000003399","DOI":"10.1097\/MS9.0000000000003399"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","unstructured":"Powles T Valderrama BP Gupta S et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024; 390: 875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","unstructured":"Patelli G Zeppellini A Spina F et al. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives. Cancer Treat Rev 2022; 104: 102351. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102351","DOI":"10.1016\/j.ctrv.2022.102351"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F Makker V Oaknin A et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024; 42: 47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.0200520231023.","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","unstructured":"Oaknin A Lee JY Makker V et al. Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-PanTumor02. Adv Ther 2024; 41: 4125\u20134139. https:\/\/doi.org\/10.1007\/s12325-024-02975-x","DOI":"10.1007\/s12325-024-02975-x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","unstructured":"Hemmati Ghavshough M Fu MZ Islam R et al. Sequential intravesical gemcitabine and docetaxel for non-muscle invasive bladder cancer: a narrative review across risk groups. Res Rep Urol 2026; 18: 584499. https:\/\/doi.org\/10.2147\/RRU.S584499","DOI":"10.2147\/RRU.S584499"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","unstructured":"Abou Chakra M Packiam VT O'Donnell MA. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer. Expert Opin Pharmacother 2023; 24: 2081\u20132091. https:\/\/doi.org\/10.1080\/14656566.2023.2271396","DOI":"10.1080\/14656566.2023.2271396"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","unstructured":"Daneshmand S Zaucha R Catto JWF et al. Erdafitinib in patients with high- and intermediate-risk non-muscle-invasive bladder cancer: final analysis of THOR-2 study. Eur Urol 2026; 89: 165\u2013173. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4152","DOI":"10.1016\/j.eururo.2025.09.4152"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","unstructured":"Catto JWF Tran B Roupr\u00eat M et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol 2024; 35: 98\u2013106. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3116","DOI":"10.1016\/j.annonc.2023.09.3116"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","unstructured":"Khattak AA Javed A Pokhrel P et al. Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG. Ann Med Surg 2025; 87: 457\u2013459. https:\/\/doi.org\/10.1097\/MS9.0000000000002938","DOI":"10.1097\/MS9.0000000000002938"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","unstructured":"John KA Odibo AO Soliman AM et al. The future of bladder cancer therapies: integrating hydrogel scaffolds for epigenetic regulator delivery. Cureus 2025; 17: e95675. https:\/\/doi.org\/10.7759\/cureus.95675","DOI":"10.7759\/cureus.95675"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","unstructured":"Keam SJ. Mitomycin intravesical solution: first approval. Clin Drug Investig 2025; 45: 909\u2013913. https:\/\/doi.org\/10.1007\/s40261-025-01475-2","DOI":"10.1007\/s40261-025-01475-2"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","unstructured":"Miyajima K Matsukawa A Yanagisawa T et al. Prognostic factors of trimodal therapy for muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 2026; 12: 486\u2013496. https:\/\/doi.org\/10.1016\/j.euf.2025.12.010","DOI":"10.1016\/j.euf.2025.12.010"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","unstructured":"Roessler N Maiorano BA Miszczyk M et al. First-line treatments for BCG-na\u00efve non-muscle invasive bladder cancer: a systematic review and meta-analysis. World J Urol 2026; 44: 76. https:\/\/doi.org\/10.1007\/s00345-025-06180-5","DOI":"10.1007\/s00345-025-06180-5"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","unstructured":"Sternberg CN Squires P Song Y et al. Evaluation of event-free survival as a surrogate endpoint for overall survival in muscle-invasive bladder cancer following neoadjuvant treatment: a systematic review and meta-analysis. Oncol Ther 2025; 13: 1225\u20131241. https:\/\/doi.org\/10.1007\/s40487-025-00399-3","DOI":"10.1007\/s40487-025-00399-3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","unstructured":"Masood S Shaikh A Brar Y. Evaluating molecular and immune biomarkers in predicting bladder cancer recurrence and survival: a systematic review. Cureus 2025; 17: e96824. https:\/\/doi.org\/10.7759\/cureus.96824","DOI":"10.7759\/cureus.96824"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","unstructured":"Tan YG Fong KY Abern MR et al. Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: a systematic review and meta-analysis. Urol Oncol 2026; 44: 119\u2013127. https:\/\/doi.org\/10.1016\/j.urolonc.2026.111091","DOI":"10.1016\/j.urolonc.2026.111091"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","unstructured":"Soma T Takemura K Toide M et al. Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Gu\u00e9rin failure: a systematic review. BMJ Oncol 2026; 5: e000753. https:\/\/doi.org\/10.1136\/bmjonc-2025-000753","DOI":"10.1136\/bmjonc-2025-000753"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","unstructured":"Deng S Meng F Wang L et al. Global research trends in non-muscle invasive bladder cancer: bibliometric and visualized analysis. Front Oncol 2022; 12: 1044830. https:\/\/doi.org\/10.3389\/fonc.2022.1044830","DOI":"10.3389\/fonc.2022.1044830"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","unstructured":"Deng Z Tang N Xiong W et al. Inflammation-related research within the field of bladder cancer: a bibliometric analysis. Front Oncol 2023; 13: 1126897. https:\/\/doi.org\/10.3389\/fonc.2023.1126897","DOI":"10.3389\/fonc.2023.1126897"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","unstructured":"Zhang Y Xu Y Li S. Bibliometrics analysis of diagnostic test accuracy studies of bladder cancer. Dis Markers 2021; 2021: 8870353. https:\/\/doi.org\/10.1155\/2021\/8870353","DOI":"10.1155\/2021\/8870353"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","unstructured":"Merton RK. The Matthew effect in Science. Science 1968; 159: 56\u201363. https:\/\/doi.org\/10.1126\/science.159.3810.56","DOI":"10.1126\/science.159.3810.56"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","unstructured":"Lobo N Martini A Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2022; 22: 361\u2013370. https:\/\/doi.org\/10.1080\/14737140.2022.2046466","DOI":"10.1080\/14737140.2022.2046466"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","unstructured":"Teo MY Rosenberg JE. Perioperative immunotherapy in muscle-invasive bladder cancer and upper tract urothelial carcinoma. Urol Clin North Am 2018; 45: 287\u2013295. https:\/\/doi.org\/10.1016\/j.ucl.2017.12.011","DOI":"10.1016\/j.ucl.2017.12.011"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","unstructured":"Thouvenin J Mart\u00ednez Chanz\u00e1 N Alhalabi O et al. Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and Future Directions. Cancers 2021; 13: 20210827. https:\/\/doi.org\/10.3390\/cancers13174341","DOI":"10.3390\/cancers13174341"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","unstructured":"Gabriel PE Horowitz A Guerrero-Ramos F et al. Therapeutic intensification based on immune checkpoint inhibitors in non-muscle invasive bladder cancer: state of the art and future perspectives. Cancers 2025; 17: 20251102. https:\/\/doi.org\/10.3390\/cancers17213555","DOI":"10.3390\/cancers17213555"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","unstructured":"Zhao L Yang J-W Chen S-Y et al. Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions. Transl Androl Urol 2026; 15: 29. https:\/\/doi.org\/10.21037\/tau-2025-717","DOI":"10.21037\/tau-2025-717"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","unstructured":"Liu W Xiao J Zou J et al. Recurrence and prevention strategies for non-muscle-invasive bladder cancer: a comprehensive review. Asian J Urol 2026; 13: 11\u201323. https:\/\/doi.org\/10.1016\/j.ajur.2024.12.008","DOI":"10.1016\/j.ajur.2024.12.008"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","unstructured":"Wu P Chen L Yang J et al. Mapping research trends in macrophage polarization and immunotherapeutic potential in prostate cancer: a bibliometric and visual analysis. Front Oncol 2026; 16: 2026. https:\/\/doi.org\/10.3389\/fonc.2026.1784198","DOI":"10.3389\/fonc.2026.1784198"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","unstructured":"Fan G Chen H Chen Y et al. Global research trends in single-port robot-assisted radical prostatectomy: a visualization-based bibliometric analysis. J Robot Surg 2026; 20: 494. https:\/\/doi.org\/10.1007\/s11701-026-03447-w","DOI":"10.1007\/s11701-026-03447-w"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","unstructured":"Shi Y. Global trends and hotspots of machine learning in the diagnosis of prostate cancer: a bibliometric analysis from 1997 to 2024. Diagn Interv Radiol 2026. https:\/\/doi.org\/10.4274\/dir.2026.263844","DOI":"10.4274\/dir.2026.263844"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261483766","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261483766","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261483766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:47:28Z","timestamp":1790923648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261483766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":39,"alternative-id":["10.1177\/03915603261483766"],"URL":"https:\/\/doi.org\/10.1177\/03915603261483766","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"03915603261483766"}}